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RESUMO O protocolo de temozolomida (TMZ) publicado em 2005 mostrou aumento importante da sobrevida dos pacientes com glioblastoma multiforme (GBM). Foi definido um protocolo de 6 meses, mas atualmente, diversos centros especializados utilizam protocolos mais longos, chegando a até 3 anos de terapia contínua. O objetivo deste estudo foi comparar a duração do tratamento nos grupos de pacientes e avaliar a sobrevida destes grupos. Foram avaliados 54 pacientes com diagnóstico de GBM operados
. This experience opened new perspectives in management of these highly malignant tumors. Stupp et al., in 2009 , reported the final results of a randomized phase III study with a median follow-up of more than five years in glioblastomas patients treated with adjuvant temozolomide and radiation 13 . A benefit from combined therapy was observed in all clinical prognostic subgroups, and methylation of the MGMT promoter was the strongest predictor for outcome 7 . In November 2004 the encouraging results of phase I and II trials with temozolomide in treatment of high grade gliomas and metastatic melanomas 2, 3, 10, 16 and the low efficacy of chemotherapy with nitrosoureas, had made us start to treat newly diagnosed glioblastomas with temozolomide as adjuvant therapy to surgery. Better quality of life, progressionfree survival and overall survival, were observed in some patients. In spite of the original trials of Stupp et al. using a 6 cycles regimen of temozolomide 14 , we have extended the treatment for those patients showing well tolerance to the drug and no tumor recurrence up to 2 years. In this report we present the results of glioblastoma patients treated at the Neurological Institute of Curitiba (INC), Brazil, with extended (> 6 cycles) adjuvant chemotherapy with temozolomide. The goals of this study were to define the prognostic factors and analyze the effects of the extended regimen of adjuvant chemotherapy with temozolomide on progression-free and overall survivals in this series.
PatIents and Methods
From November 2004 to July 2009, 941 patients with brain tumors were surgically treated at the Neurological Institute of Curitiba, Brazil. Sixty two patients presented diagnosis of a glioblastoma in the histopathological examination. All clinical records were reviewed and 8 patients were excluded from this due to adjuvant therapy performed in other clinics. The data of the remaining 54 patients were retrospectively analyzed according to age, gender, Karnofsky Performance Scale (KPS) at diagnosis, side and localization of tumor, grade of surgical removal, period of use of temozolomide until recurrence, progression-free survival, KPS after recurrence and overall survival.
There were 36 males (66.7%) and 18 females (33.3%). The mean age of patients at admission was 55.2 + 13.7 (range 18 to 84 years). Six patients were under 40 years of age, 32 patients between 40 and 60 years, 11 patients between 60 and 80 years and 2 patients over 80 years. Forty seven patients (87%) presented a KPS 70 or higher at diagnosis and seven (13%) a KPS under 70. Tumor location was in the right hemisphere in 55% of patients, 43% in the left and bilateral in 2% of the cases.
In 35% of the cases it was located in the temporal lobe, 32% in the frontal lobe, 23% in parietal lobe, 6% in the occipital lobe and 4% in corpus callosum (Table 1) . MRI with gadolinium was performed in all cases in the first 72 hours after surgery to evaluate the extension of tumor removal. Grade of tumor resection was classified according to the postoperative MRI (volume of resected enhancing lesion) as: total (>98%), near total (70-98%), partial (<70%) and biopsy (stereotatic). All patients received adjuvant radiotherapy. Radiotherapy was delivered through a linear accelerator (6/15 Mv) and the dosis used was 60 Gy in all patients. Forty patients received concomitant adjuvant radiotherapy and chemotherapy with temozolomide. Chemotherapy with temozolomide was started with the irradiation at the following According to uni and multi-varied analysis in this series there was no statistic significant correlation between survival and age < 45 (p=0.64), gender (p=0.98), KPS at diagnosis (p=0.84) and grade of resection (p=0.69). Localization of tumors in the frontal or parietal lobe was marginally (shorter survival) of statistic significance (p=0.08). Figure 1 shows a Kaplan-Meier curve of the overall survival (in months) of 54 patients of this series. The overall survival in 6, 12, 18 and 24 months were 96,3%, 72,6%, 58,1% and 43,5% respectively.
regimen: 75 mg/m2 every day during radiation period, 28 days with no treatment, following by cycles every 28 days with a dose of 200 mg/m2 (D1 to D5). Toxicity of chemotherapy was counted according to the National Cancer Institute Common Toxicity Criteria, version 3 (CCTC), described by Trotti et al 15 . All data were statistically analyzed using Kaplan-Meir curves, Anova test, multivariate logistic regression models and Pearson´s correlation. Kaplan-Meir curves demonstrated survival according the studied prognostic factors. To identify the independent factors associated with death the multivariate logistic regression model was used. To study the length of temozolomide treatment and progression-free survival and overall survival the Pearson´s correlation model was utilized. Analysis of variance was used to study the correlation between the period of use of temozolomide with the mean survival time.
A minimum level of significance of 5% was considered for all statistic tests. The end point of this study was July 2010.
results
Total resection was achieved in 51.8% of patients (28:54), near total in 24% (13:54), partial in 12.9% (7:54) and only biopsy in 11.1% (6:54). Twenty four patients followed an extended temozolomide regimen, 6 (11.1%) were treated > 12 months and 18 (33.3%) from 6 to 12 months. Sixteen patients (29.6%) received up to 6 cycles and 14 patients did not receive any temozolomide ( Table 2) . Causes of interruption of temozolomide following by treatment with other chemotherapic agent were: tumor progression in 65% (26:40), mild toxicity (CCTC grades 1 and 2) in 20% (8:40), moderate to severe toxicity (CCTC grades 3 and 4) in 5% (2:40) and other (pneumonia due to aspiration and Fournier syndrome) in 10% (4:10).
The mean-time of use of temozolomide and second line chemotherapy drugs, the mean PFS and the KPS on recurrence are presented in Table 3 . At the end of the analysis of the data (mean follow-up of 14.4 months ranging from 1 to 44 months) 10 patients (18.5%) were alive.
The length of treatment with TMZ before recurrence showed a strong positive correlation (r=0.66) with survival time up to 15 months (Figure 2 ). There was also correlation (r=0.64) between length of use of TMZ and progression free-survival (Figure 3) . Patients receiving treatment with TMZ presented longer survival when compared to those not treated with TMZ. In this series there was no statistic difference on survival between patients receiving TMZ up to 6 or 12 months ( Figure  4 ). Longer survival (p=0.04) was, however observed in those treated more than 12 months.
DIscussIon
In 2005, Stupp et al., demonstrated the benefits of temozolomide in the treatment of high grade gliomas 14 . This drug became the most used adjuvant therapy for these fatal tumors. The long-term efficacy of temozolomide in glioblastomas was reported by the same authors 13 . In the group of patients treated postoperatively with concomitant radiotherapy and temozolomide 27.2% survived two years and 9.8% five years. In patients treated with radiotherapy only, the overall survival was 10.9% and 1.9% in 2 and 5 years respectively 13 . These authors initially proposed a 6-cicles chemotherapy regimen but long-term treatment of responding patients up to 8 years was reported 1, 6, 8 . The low myelotoxicity and easy administration of this drug facilitates its utilization as adjuvant chemotherapy for high grade gliomas. Treatment periods longer than 6 cicles have been used at many neuro-oncologic center even without clinical studies demonstrating clear benefits of prolonged use of this drug 6, 8, 11, 12 . Recently, Seiz et al., demonstrated that patients treated with extended temozolomide regimen (over 6-cicles) presented longer survival (p<0.0001) 12 . In our series the benefits of extended postoperative adjuvant chemotherapy (over 6-cicles) concomitant with radiotherapy was observed (24:60 -60% of cases). These results could be clearly demonstrated by the analysis of variance and Pearson's correlation (Figures 2 and 3) . Both tests showed strong correlation between prolonged use of temozolomide and longer survival, and disease free progression time (r=0.66 and r=0.64). Figure 4 shows benefits on survival with extended use of the drug up to 15 months. After this period, survival and control of the disease dropped (figures 2 and 3). In our series and in the reported study of Seiz et al. 12 , age and extend of tumor resection showed no influence in survival (p=0.64 and p=0.69 respectively). These observations demonstrate the benefits of the extended use of temozolomide in a selected group of patients (responder patients). In general temozolomide is well tolerated and side-effects are rare (15%) even with prolonged use 6, 8, 12 . Krhasraw et al observed no side-effect in three patients submitted to long-term treatment 8 . In our series 20% presented side-effects but only 5% were severe (grade 3 or 4). This tolerance to the drug had permitted the extended use in our patients. There are, however, reports in the literature describing late side-effects of this drug as systemic infections and induced tumors 1, 4, 5 . Severe side-effects like aplastic anemia have been reported in the first months of treatment or during concomitant radiotherapy 9 . Glioblastoma is a devastating disease and tumor recurrence is frequent in the first 8 to 12 months after diagnosis (8 months in this series). In our opinion there is no reason to treat these patients, especially "responder patients", only with a 6-cicles of adjuvant chemotherapy. This was the reason to extend treatment at least to 12-cicles in our cases. The length of use of temozolomide was dependent to clinical response, side-effects and MRI findings. This study supports an extended use of this drug up to 15 months, if the patient tolerates it well.
Longer treatment showed no benefits in this series (Pearson's correlation test - Figures 2 and 3) but the small number of cases do not permit clear conclusion of the length of use of temozolomide.
conclusIon
The extended postoperative adjuvant treatment with temozolomide for patients with high grade gliomas and glioblastomas has been reported in neuro-oncologic meetings and in the literature 6, 8, 11, 12 . There is, however, at the moment, no controlled study demonstrating its benefits. This series, despite of the small number of cases, could clearly show longer survival in patients treated with 15-cicles over patients treated with 6 or 12-cicles.
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